Clinical Research Directory
Browse clinical research sites, groups, and studies.
Immunogenicity and Safety of Sequential 2vHPV-9vHPV Vaccination in Girls Aged 9-14 Years
Sponsor: Zhejiang Provincial Center for Disease Control and Prevention
Summary
This study aims to assess the immunogenicity and safety of a sequential 2vhpv to 9vhpv immunization schedule in girls aged 9-14 years
Official title: Immunogenicity and Safety of Sequential Bivalent and 9-Valent Human Papillomavirus Vaccine Immunization in Girls Aged 9-14 Years
Key Details
Gender
FEMALE
Age Range
9 Years - 14 Years
Study Type
INTERVENTIONAL
Enrollment
400
Start Date
2025-12-20
Completion Date
2029-11-13
Last Updated
2025-12-15
Healthy Volunteers
Yes
Conditions
Interventions
bivalent HPV vaccine
Bivalent HPV vaccine produced by Shanghai Zerun Biotechnology Co.,Ltd. or Wantai BioPharm.
9-valent HPV vaccine
9-valent HPV vaccine is produced by Wantai BioPharm or Merck Sharp \& Dohme LLC.
Locations (1)
Jinyun center for Disease Control and Prevention
Lishui, Zhejiang, China